Home >
World Psoriasis Day 2019
2019/10/29
Today, IFPA presents World Psoriasis Day, as an annual day dedicated to people with psoriasis and/or psoriatic arthritis. It has been celebrated on October 29 for more than a decade. On World Psoriasis Day, our member associations and their supporters organise activities around the world to raise awareness of psoriasis.
To see examples of all the activities our members put on in around the world last World Psoriasis Day, visit worldpsoriasisday2018.com.
Aim of World Psoriasis Day
World Psoriasis Day is dedicated to people living with psoriasis or psoriatic arthritis. On October 29, we aim to address their needs:
Raise awareness
Psoriasis affects over 125 million people around the world – not just physically, but also socially, emotionally and financially. World Psoriasis Day aims to raise the profile of this debilitating disease and increase awareness of the effect it has on people’s lives.
Spread information
For many, psoriasis is still a relatively unknown disease. On World Psoriasis Day, IFPA spreads information about psoriasis, dispel common myths and answer questions. They also inform patients about their own condition, so they can feel empowered to speak about it.
Improve access to treatment
On World Psoriasis Day, IFPA lobby to give people with psoriasis better access to appropriate, affordable treatment. That’s why they specifically address key health decision-makers like national governments, policy-makers and healthcare providers that day.
Give the psoriasis community a voice
Many people living with psoriasis may struggle to get the world to listen to their needs. World Psoriasis Day is an opportunity for the psoriasis community to speak out from a common platform – and have its voice heard.
Are there special World Psoriasis Day activities?
Yes! Each year, IFPA member associations organise a wide variety of World Psoriasis Day activities – from small gatherings to large-scale events. Examples of activities include:
Awareness-raising walks or running events
Free information events for the general public
Lectures or seminars held by medical professionals
Handing out flyers and brochures in public places
Drawing competitions
Sending out WPD postcards
Free psoriasis assessment and consultations at hospitals
Activities for children and youth
Photo exhibitions with psoriasis-related themes
Radio or TV interviews with patient leaders or medical experts
Fundraising barbecues, get-togethers or concerts
Outdoor yoga sessions for people with psoriasis
Coverage of World Psoriasis Day by local or national media
Can I join World Psoriasis Day?
Of course! World Psoriasis Day is open to anyone – whether you have psoriasis yourself, know someone who does or simply want to support people living with psoriasis.
To be part of World Psoriasis Day, you can:
Contact your national psoriasis association to find out about their plans for October 29.
Organise an activity yourself. Perhaps your national association isn’t planning anything or you live in a country without an active psoriasis association? Don’t let this stop you! Organising a workshop, an awareness-raising walk, or simply handing out flyers can be a great way to let your community know about World Psoriasis Day. If you organise something, we’d love to hear about it! That way, IFPA can help promote your activity and share some pictures afterwards for our global audience.
Follow IFPA on Facebook or Twitter to get the latest updates on IFPA’s World Psoriasis Day campaigns and plans.
Spread the word about World Psoriasis Day, wear orange and blue on October 29, or reach out to someone from the psoriasis community to let them know you are there for them.
SOURCE: https://ifpa-pso.com/our-actions/world-psoriasis-day/
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis.
Arch Dermatol Res.
2021 Apr , 313, (3):163-171.
Psoriasis, hidradenitis, and atopic dermatitis (AD) are associated with increased cardiometabolic comorbidities. Yet, little is known about screening rates for cardiometabolic comorbidities in patients with these disorders. The objective of this study is to determine rates and predictors of cardiovascular screening among patients with psoriasis, AD, and hidradenitis in the United States. Data from the 2006-2015 National Ambulatory Medical Care Survey were analyzed, including 67,581 (...)
see on pubmed
Nanoliposomes@Transcutol for Skin Delivery of 8-Methoxypsoralen.
Sinico C et al.
Nanoliposomes@Transcutol for Skin Delivery of 8-Methoxypsoralen.
J Nanosci Nanotechnol.
2021 May 01, 21, (5):2901-2906.
8-methoxypsoralen is the most common drug in psoralen plus ultraviolet light irradiation therapy for the treatment of severe psoriasis. Despite of the efficacy, its classic oral administration leads to several serious adverse effects. However, the topical psoralen application produces a drug skin accumulation lower than that obtained by oral administration, due to the drug low skin permeability. In this paper, 8-methoxypsoralen loaded Penetration Enhancer-containing Vesicles were prepared (...)
see on pubmed
Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-κB and MAPKs signaling pathways.
Bioengineered.
2021 Dec , 12, (1):183-195.
Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of worldwide population, and causing long-term troubles to the patients. Therefore, it is urgent to develop safe and effective therapeutic drugs. Catalpol is a natural iridoid glucoside, that has several remarkable pharmacological effects, however, whether catalpol can alleviated psoriasis has not been explored. The goal of the present work is to study the role of catalpol in psoriasis in vivo and in vitro. (...)
see on pubmed
on Atopic Dermatitis
Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis.
Arch Dermatol Res.
2021 Apr , 313, (3):163-171.
Psoriasis, hidradenitis, and atopic dermatitis (AD) are associated with increased cardiometabolic comorbidities. Yet, little is known about screening rates for cardiometabolic comorbidities in patients with these disorders. The objective of this study is to determine rates and predictors of cardiovascular screening among patients with psoriasis, AD, and hidradenitis in the United States. Data from the 2006-2015 National Ambulatory Medical Care Survey were analyzed, including 67,581 (...)
see on pubmed
Qingxue jiedu formulation ameliorated DNFB-induced atopic dermatitis by inhibiting STAT3/MAPK/NF-κB signaling pathways.
J Ethnopharmacol.
2021 Apr 24, 270:113773.
Qingxue jiedu Formulation (QF) is composed of two classic prescriptions which have been clinically used for more than 5 centuries and appropriately modified through basic theory of traditional Chinese medicine for treating various skin inflammation such as atopic dermatitis (AD), acute dermatitis and rash. Although QF possesses a prominent clinical therapeutic effect, seldom pharmacological studies on its anti-AD activity are (...)
see on pubmed
Methicillin-resistant from infected skin lesions present several virulence genes and are associated with the CC30 in Brazilian children with atopic dermatitis.
Virulence.
2021 Dec , 12, (1):260-269.
Atopic dermatitis (AD) is a chronic inflammatory skin disease and colonization by may affect up to 100% of these patients. Virulent and resistant isolates can worsen AD patient clinical condition and jeopardize the treatment. We aimed to detect virulence genes and to evaluate the biofilm production of isolates from infected skin lesions of children with AD. Methicillin resistance was detected by phenotypic and molecular tests and the virulence genes were detected by PCR. Biofilm formation (...)
see on pubmed
